tiprankstipranks
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
2M ago
Rising High: Organigram acquires Motif Labs for C$90M upfront
Premium
The Fly
Rising High: Organigram acquires Motif Labs for C$90M upfront
2M ago
Relmada Therapeutics commences exploration of strategic alternatives
Premium
The Fly
Relmada Therapeutics commences exploration of strategic alternatives
2M ago
Relmada Therapeutics downgraded to Market Perform from Outperform at Leerink
PremiumThe FlyRelmada Therapeutics downgraded to Market Perform from Outperform at Leerink
2M ago
Relmada Therapeutics Faces Setback in Phase 3 Study
Premium
Company Announcements
Relmada Therapeutics Faces Setback in Phase 3 Study
2M ago
Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile
Premium
The Fly
Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile
2M ago
Relmada Therapeutics reports Q3 EPS (72c), consensus (64c)
PremiumThe FlyRelmada Therapeutics reports Q3 EPS (72c), consensus (64c)
3M ago
Relmada Therapeutics reports Q3 EPS (72c), consensus (64c)
Premium
The Fly
Relmada Therapeutics reports Q3 EPS (72c), consensus (64c)
3M ago
Rising High: Exclusive talk with house of brands Carma HoldCo
Premium
The Fly
Rising High: Exclusive talk with house of brands Carma HoldCo
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100